** Amgen AMGN.O said on Thursday its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to speculate on the impact of U.S. tariffs, tax policy would be a more effective way to influence U.S. manufacturing
** Median PT of brokerages covering the stock is $315.46 - data compiled by LSEG
FOCUS REMAINS ON MARITIDE
** Mizuho ("Neutral", PT: $235) believes many questions remain unanswered on experimental weight-loss drug MariTide, viewed by many investors as a potential blockbuster
** J.P.Morgan ("Neutral", PT: $283.78) expects shares to "remain range bound pending longer-term obesity updates for MariTide"
** RBC Capital Markets ("Outperform", PT: $320) believes greater visibility into critical inflection points for Horizon-derived products in the rare disease space, like thyroid eye disease drug Tepezza, gout treatment Krystexxa, and immune disorder drug Uplizna is necessary to bolster investor confidence
** Piper Sandler ("Overweight", PT: $329) says Amgen's strategy of launching new biosimilars will help in "cushioning the impact" by offsetting the revenue loss from products losing their patent protection
** Citi ("Neutral", PT: $300) says they are positive of AMGN's rare product portfolio from the Horizon acquisition
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.